Publications by authors named "James Peace"

Claim this Profile
S
Safety and Efficacy of a Preservative-Free Bimatoprost 0.01% Ophthalmic Gel: Results From a Phase III Controlled Trial.
Eydie Miller-Ellis, James H Peace, Douglas G Day, Sherif M El-Harazi, Sylvie Nissle

J Glaucoma· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of AGN-241622 for Presbyopia: Results From a First-in-Human, Phase 1/2, Randomized, Vehicle-Controlled Study.
Sherif M El-Harazi, James H Peace, Ashley Nguyen, Jiang Yuan, Susan Lee

J Ocul Pharmacol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-Masked, Dose-Response, Vehicle-Controlled Study of VVN461 Ophthalmic Solution in Postoperative Ocular Inflammation.
James H Peace, Kevin Y Jong, Jason Bacharach, Xiao-Yan Li, Wang Shen

Ophthalmol Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Shane Kannarr, Sherif M El-Harazi, Majid Moshirfar, Christopher Lievens, Jennifer Lee Kim, James H Peace

Am J Ophthalmol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension.
Bridgitte Shen Lee, Ranjan Malhotra, Kenneth Sall, Brittany Mitchell, James Peace

Clin Ophthalmol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension.
David Wirta, Ranjan Malhotra, James Peace, Bridgitte Shen Lee, Brittany Mitchell

Eye Contact Lens· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
James H Peace, Hayley J McKee, Casey C Kopczynski

Ophthalmol Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
Raymond Fong, Bruce E Silverstein, James H Peace, Jon I Williams, Jason L Vittitow

J Cataract Refract Surg· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Rebecca Stacy, Kenneth Huttner, Jen Watts, James Peace, David Wirta

Am J Ophthalmol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
Kelly K Nichols, Edward Holland, Melissa M Toyos, James H Peace, Parag Majmudar

Clin Ophthalmol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Felipe A Medeiros, Keith R Martin, James Peace, Baldo Scassellati Sforzolini, Jason L Vittitow

Am J Ophthalmol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
James H Peace, Peter Ahlberg, Mathias Wagner, John M Lim, David Wirta

Am J Ophthalmol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
Thomas R Walters, Damien F Goldberg, James H Peace, James A Gow,

Ophthalmology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile and predictors of normal ganglion cell-inner plexiform layer thickness measured with frequency-domain optical coherence tomography.
Jean-Claude Mwanza, Mary K Durbin, Donald L Budenz, Christopher A Girkin, Christopher K Leung, James H Peace

Invest Ophthalmol Vis Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
Steven M Silverstein, Melissa G Cable, Ehsan Sadri, James H Peace, Raymond Fong

Curr Med Res Opin· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery.
Stephen Smith, Douglas Lorenz, James Peace, Kimberly McLeod, R S Crockett

Clin Ophthalmol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy.
J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart

Clin Ophthalmol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension.
Douglas J Rhee, James H Peace, Sushanta Mallick, Theresa A Landry, Michael V W Bergamini

Clin Ophthalmol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of IOP reduction with travoprost BAK-free solution.
Ronald L Gross, James H Peace, Stephen E Smith, Thomas R Walters, Harvey B Dubiner

J Glaucoma· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension.
Robert J Noecker, Melissa L Earl, Tom Mundorf, James Peace, Robert D Williams

Adv Ther· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis